“The fourth quarter of 2022 was another record quarter for Akoya, demonstrating our continued business momentum and commercial execution. In 2022, we delivered strong financial performance and saw growing adoption of our spatial biology platforms across the discovery, translational, and clinical markets,” said Brian McKelligon, Chief Executive Officer.
